Deutsche Bank AG Purchases New Shares in Organogenesis $ORGO

Key Points

• Deutsche Bank initiated a position in Organogenesis by purchasing 1.71 million shares worth approximately $4.15 million, representing about 1.33% of the company. Institutional investors and hedge funds collectively own 49.57% of ORGO.
• Analyst sentiment weakened, with several firms downgrading the stock and Truist Financial cutting its price target to $2.00. The consensus rating is “Reduce,” with an average price target of $4.33.
• Organogenesis reported a quarterly loss of $0.71 per share and revenue of $43.76 million, missing estimates for both earnings and sales. The stock opened at $1.74, near its 12-month low of $1.54.

Deutsche Bank AG purchased a new position in Organogenesis (NASDAQ:ORGO - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 1,706,186 shares of the company's stock, valued at approximately $4,146,000. Deutsche Bank AG owned approximately 1.33% of Organogenesis as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently added to or reduced their stakes in ORGO. Strs Ohio acquired a new stake in shares of Organogenesis in the first quarter valued at about $105,000. Creative Planning increased its stake in shares of Organogenesis by 84.5% during the second quarter. Creative Planning now owns 35,392 shares of the company's stock worth $130,000 after purchasing an additional 16,205 shares in the last quarter. Cetera Investment Advisers acquired a new position in shares of Organogenesis during the 2nd quarter worth about $222,000. American Century Companies Inc. raised its position in shares of Organogenesis by 25.6% during the 2nd quarter. American Century Companies Inc. now owns 164,793 shares of the company's stock worth $603,000 after purchasing an additional 33,573 shares during the last quarter. Finally, Russell Investments Group Ltd. lifted its stake in Organogenesis by 36.6% in the 2nd quarter. Russell Investments Group Ltd. now owns 168,152 shares of the company's stock valued at $617,000 after buying an additional 45,021 shares in the last quarter. 49.57% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts recently issued reports on ORGO shares. Weiss Ratings cut Organogenesis from a "sell (d)" rating to a "sell (d-)" rating in a report on Friday. Wall Street Zen cut Organogenesis from a "sell" rating to a "strong sell" rating in a report on Saturday, August 8th. Truist Financial decreased their target price on Organogenesis from $3.00 to $2.00 and set a "hold" rating on the stock in a research report on Friday, August 7th. BTIG Research lowered Organogenesis from a "buy" rating to a "neutral" rating in a research note on Friday, May 8th. Finally, UBS Group set a $3.00 price target on Organogenesis in a research report on Thursday, May 28th. Two research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Reduce" and a consensus price target of $4.33.

Organogenesis Stock Performance

ORGO opened at $1.74 on Wednesday. Organogenesis has a twelve month low of $1.54 and a twelve month high of $7.08. The firm has a market capitalization of $223.90 million, a PE ratio of -2.02 and a beta of 1.34. The company has a current ratio of 3.52, a quick ratio of 3.00 and a debt-to-equity ratio of 0.07. The firm's 50-day moving average price is $2.28 and its 200 day moving average price is $2.57.

Organogenesis (NASDAQ:ORGO - Get Free Report) last released its earnings results on Thursday, August 6th. The company reported ($0.71) earnings per share for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.36). The business had revenue of $43.76 million during the quarter, compared to analysts' expectations of $54.27 million. Organogenesis had a negative return on equity of 23.89% and a negative net margin of 19.94%.

Organogenesis Profile

Organogenesis Inc operates as a regenerative medicine company focused on the development, manufacturing and commercialization of therapeutic solutions for wound care, surgical repair and sports medicine. The company's product portfolio addresses a range of acute and chronic tissue repair needs, leveraging bioengineered skin substitutes, human placental-derived products and other allografts designed to promote healing and reduce scarring. Organogenesis markets its therapies to hospitals, outpatient clinics, wound care centers and other healthcare providers.

Key offerings include Apligraf, a living skin substitute for treatment of diabetic foot ulcers and venous leg ulcers; Dermagraft, a cryopreserved human fibroblast-derived dermal substitute; Grafix, a placental membrane allograft for complex and chronic wounds; and TheraSkin, a cryopreserved human skin allograft used in surgical and reconstructive procedures.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source